Children’s - Minnesota is one of the largest pediatric health systems in the United States and the only health system in Minnesota to provide care exclusively to children. An independent and not-for-profit system since 1924, Children’s serves kids throughout the Upper Midwest at two free-standing hospitals (Minneapolis and St. Paul), 12 primary and specialty-care clinics and six rehabilitation sites.

Children's currently offers ASHP accredited residencies for: 3 PGY1 residents, 1 PGY2 pediatric specialty resident and 1 PGY2 pharmacogenomics pharmacy resident (accreditation survey completed 9/2020). 

The PGY 2 Pharmacogenomics pharmacy residency will provide the resident the expertise to implement a successful clinical pharmacogenomics program. The PGY 2 resident will gain experience interpreting pharmacogenomic test results, creating pharmacogenomic clinical consults, and developing electronic clinical decision support tools for the Children’s Minnesota electronic health record. Strengths of the program include use of a broad multi-gene test panel, a multi-disciplinary implementation committee and commitment to becoming a leader in pharmacogenomic clinical services. The institution’s integration of the electronic health record which spans inpatient acute care services and ambulatory care clinics allows for this implementation across the spectrum of care. The PGY2 resident will provide direct patient care in a pharmacogenomics specialty clinic in addition to other ambulatory and inpatient services. Pharmacists at Children’s Minnesota practice in the context of an integrated pharmaceutical care approach. The resident will provide leadership integrating clinical pharmacogenomics in this context.

The PGY2 resident will be a department educator and will provide pharmacist CE programs, journal clubs, student preceptorship, and didactic instruction to pharmacy students at the University of Minnesota College of Pharmacy. The PGY2 resident will have increased responsibility with hospital committees providing leadership for the clinical pharmacogenomics implementation.